DR3 signaling protects against cisplatin nephrotoxicity mediated by tumor necrosis factor

Am J Pathol. 2012 Apr;180(4):1454-64. doi: 10.1016/j.ajpath.2012.01.003. Epub 2012 Feb 11.

Abstract

The expression of death receptor 3 (DR3), a member of the tumor necrosis factor (TNF) receptor superfamily, is up-regulated in human tubular epithelial cells (TECs) during renal injury, but its function in this setting remains unknown. We used cisplatin to induce renal injury in wild-type (DR3(+/+)) or congenitally deficient DR3(-/-) mice to examine the in vivo role of DR3. Cisplatin induced the expression of DR3, its ligand, TNF-like ligand 1A (TL1A), and TNF in TECs, as observed in human renal injury. Cisplatin increased apoptotic death of DR3(-/-) TECs by twofold compared with DR3(+/+) TECs, whereas it reduced the number of tubules expressing phospho-NF-κBp65(Ser276) by 50% at 72 hours. Similar degrees of induction of DR3, TL1A, and TNF, and changes in apoptosis and phospho-NF-κBp65(Ser276), were obtained in mouse kidney organ cultures treated with cisplatin for 3 hours, suggesting a direct effect on TECs. TNF was implicated in mediating cisplatin-induced tubular damage given that the in vivo co-administration of GM6001, an inhibitor of TNF maturation and release, significantly reduced TNF production and tubular damage. Moreover, TNF exacerbated, whereas TL1A reduced, cisplatin-induced apoptosis in the DR3(+/+) mouse proximal tubule cell line, TKPTS. Our data demonstrate that cisplatin-induced nephrotoxicity is mitigated by DR3 signaling, suggesting that this occurs by antagonizing pro-apoptotic signals induced by TNF. Therefore, activating DR3 may be beneficial in reducing acute kidney injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / metabolism
  • Acute Kidney Injury / pathology*
  • Animals
  • Apoptosis / drug effects
  • Cisplatin / pharmacology
  • Dipeptides / pharmacology
  • Drug Interactions
  • Epithelial Cells / drug effects
  • Epithelial Cells / metabolism
  • Epithelial Cells / pathology
  • Kidney Tubules / drug effects
  • Kidney Tubules / metabolism
  • Kidney Tubules / pathology
  • Kidney Tubules, Proximal / drug effects
  • Kidney Tubules, Proximal / pathology
  • Ligands
  • Mice
  • Mice, Mutant Strains
  • NF-kappa B / metabolism
  • Organ Culture Techniques
  • Phosphorylation / drug effects
  • Protease Inhibitors / pharmacology
  • Receptors, Tumor Necrosis Factor, Member 25 / biosynthesis
  • Receptors, Tumor Necrosis Factor, Member 25 / deficiency
  • Receptors, Tumor Necrosis Factor, Member 25 / physiology*
  • Signal Transduction / physiology
  • Tumor Necrosis Factor Ligand Superfamily Member 15 / biosynthesis
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Tumor Necrosis Factor-alpha / physiology*
  • Up-Regulation / drug effects

Substances

  • Dipeptides
  • Ligands
  • N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide
  • NF-kappa B
  • Protease Inhibitors
  • Receptors, Tumor Necrosis Factor, Member 25
  • Tnfsf15 protein, mouse
  • Tumor Necrosis Factor Ligand Superfamily Member 15
  • Tumor Necrosis Factor-alpha
  • Cisplatin